Publication: Clinical evaluation of the 'Siriraj spacer' in asthmatic Thai children
3
Issued Date
1992-01-01
Resource Type
ISSN
00034738
Other identifier(s)
2-s2.0-0026440591
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Annals of Allergy. Vol.69, No.5 (1992), 433-438
Suggested Citation
P. Vichyanond, K. Chokephaibulkit, S. Kerdsomnuig, N. Visitsuntorn, M. Tuchinda Clinical evaluation of the 'Siriraj spacer' in asthmatic Thai children. Annals of Allergy. Vol.69, No.5 (1992), 433-438. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/22435
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Clinical evaluation of the 'Siriraj spacer' in asthmatic Thai children
Other Contributor(s)
Abstract
We designed a new, washable, and collapsible bag spacer (the Siriraj Spacer) for use with metered-dose inhalers (MDI) by Thai asthmatic patients. The Siriraj Spacer consists of a mouthpiece, a front panel to which any type of MDI could be attached and a collapsible 800 mL ringed-plastic bag. Fifteen asthmatic children (6-13 years of age) were enrolled into a randomized, double-blind, triple crossover study (spanning a period of three days) to compare the clinical effectiveness of the Siriraj Spacer with that of the Volumatic Spacer (Glaxo, Inc., Research Triangle Park, NC, U.S.A.) and with the use of MDI alone. Medication used with the active method of administration was 2 puffs of albuterol (100 μg/puff) while 2 puffs from placebo MDI were used with the other two methods in succession. All children were stable asthmatic patients, and had been instructed how to use MDI properly by an open mouth technique just before the initiation of the study. Spirometry (FEV1, FVC, PEFR, and FEF(25-75%)) was followed for six hours after the administration of albuterol. The baseline FEV1s of the three study days were within 50% to 70% of the predicted values (with baseline variability of less than 20%). Data were expressed as percentage of improvement from baseline. By an analysis of variance with repeated measures, no significant differences were observed between pulmonary function data obtained with any of the three methods of bronchodilator administration (P > .05) at any time point throughout the 6-hour period. The lack of clinical advantage of any of the two tested spacers over the use of the MDI alone could be due to the close proximity of MDI instruction to the study time and possibly due to the high motivation in this group of children. Due to its low cost, its portability and its washability (hence, retarding the rate of fungal growth in the bag itself), the Siriraj Spacer is considered to be a proper adjunct to the treatment of asthma in patients who cannot be properly instructed to use MDIs.